European Pharmaceutical Review

JUNE 12, 2024

The main objective was to evaluate the efficacy and safety of MBK-01 compared to fidaxomicin, providing significant insights into the potential of MBK-01 as a treatment for primary or recurrent CDI and contributing to the advancement of microbiome-based therapies. 2016; 46: 479–93. Adverse events were relatively low in both groups (2.22

Safety 111

Safety Patients Side effects Management 111

pharmaphorum

AUGUST 11, 2022

In 2016, the estimated annual cost of drug-related morbidity and mortality resulting from non-optimised medication therapy was $528.4 This means that hyper-metabolisers would need their dosage to be increased to achieve the desired effect. billion in the United States alone.

Side effects 98

Side effects Medical Prescription Patients 98

Medgadget

MAY 2, 2023

These treatments at times come with a long list of side effects, leaving many patients in search of an effective long-term solution. For some patients with PTSD, psychotherapy may not be an effective option, they may find talking about their traumatic experience stress inducing, untherapeutic or ineffective.

Side effects 86

Side effects Prescription Healthcare Healthcare 86

European Pharmaceutical Review

JULY 20, 2022

Withdrawing drugs over safety concerns requires careful analysis of the health benefits and risks by regulators. Monitoring and studying the side effects of licensed medicines is an essential part of drug development to ensure public safety. Supporting regulators. It focused on data from France, Germany and the UK.

Medicine 97

Medicine Safety Side effects Electronics 97

European Pharmaceutical Review

JULY 5, 2022

There is an urgent need for more effective chemotherapy treatments with less severe toxicity and side effects. Irinotecan – also known by the brand name Campto/Camptosar ® (Pfizer Ltd.) – has proven to be an effective chemotherapy agent against several types of gastrointestinal cancer. 5): V38-V49.

Patients 104

Patients Food and Drug Administration Side effects Safety 104

European Pharmaceutical Review

SEPTEMBER 22, 2023

While new positive clinical data with anti-Abeta mAbs signal tremendous advancement and proof‑of-concept for the whole field, it is believed that the observed effects could still be improved and optimised in terms of greater clinical benefits, lower side effects and enhanced treatment convenience.

Food and Drug Administration 97

Food and Drug Administration Safety Patients Leads 97

European Pharmaceutical Review

DECEMBER 14, 2023

Over the past few years, we have researched the types of evidence used in regulatory decisions for drug product withdrawals due to safety concerns in Europe. Our research showed that in Europe between 1999 and 2016, 35 products were withdrawn. But over time, trends in what evidence is most available and therefore most used, change.

Medicine 116

Medicine Safety Competition Medical 116